MeVis Medical Solutions (M3V) AI Stock Analysis

• Market Cap: €45.86M
• Dividend Yield: 3.68%
• Average Volume (3M): 51.00
• Price to Earnings (P/E): 10.7
• Beta (1Y): 0.06
• Revenue Growth: -5.72%
• EPS Growth: -25.19%
• Country: DE
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.32
• Shares Outstanding: 1,820,000
• 10 Day Avg. Volume: 74
• 30 Day Avg. Volume: 51
• PEG Ratio: -1.30
• Price to Book (P/B): 2.35
• Price to Sales (P/S): 2.47
• P/FCF Ratio: 14.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 80 Outperform
• Price Target: ―

MeVis Medical Solutions is a financially robust company with strong profitability and a stable balance sheet, reflected in its financial performance score. The stock's positive technical indicators and low volatility further enhance its attractiveness. Valuation metrics suggest potential undervaluation, with a solid dividend yield providing additional appeal. However, challenges in net income efficiency and cash flow generation highlight areas for improvement. Overall, the stock presents a compelling investment opportunity with moderate risks.

MeVis Medical Solutions Business Overview & Revenue Model

Company Description

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological disorders. It offers X-ray modalities, including computed tomography, digital mammography, digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. The company also offers three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians, as well as internet-based special applications in teleradiology. In addition, its services are used for technical visualization and online training. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Deutschland AG.

How the Company Makes Money

MeVis Medical Solutions generates revenue through the sale and licensing of its proprietary software solutions to healthcare providers, hospitals, and medical research facilities. The company also offers maintenance and support services, which provide a recurring revenue stream. Additionally, MeVis partners with major medical device manufacturers to integrate its software into imaging systems, earning revenue from these strategic collaborations. The company benefits from long-term contracts and partnerships with leading healthcare organizations, ensuring a steady flow of income.

MeVis Medical Solutions Financial Statement Overview

Summary

MeVis Medical Solutions exhibits strong profitability and a robust balance sheet with no debt, which is a significant strength. However, declining net profit margins and cash flow metrics suggest potential areas for improvement. Stability in revenue and effective cost management are positives, but the company should focus on enhancing net income efficiency and cash flow generation to maintain its financial health.

Income Statement

MeVis Medical Solutions shows a solid gross profit margin of approximately 97% over the years, indicating strong profitability. However, the net profit margin has seen a decline from 43.5% in 2019 to 26.9% in 2023, which may suggest challenges in maintaining net profitability. Revenue has been relatively stable with a slight decrease in the most recent year. The consistency in EBITDA margins above 28% signals effective operational management.

Balance Sheet

The company maintains a strong balance sheet with zero debt, resulting in a commendable debt-to-equity ratio. The equity ratio remains stable at around 64%, reflecting financial stability. However, the return on equity has decreased from 45.3% in 2019 to 25.6% in 2023, indicating reduced efficiency in generating returns from equity. Strong cash reserves further bolster the company's financial position.

Cash Flow

Free cash flow has generally been positive, with a notable growth rate in earlier years. However, recent declines in operating cash flow and free cash flow are concerning. The ratio of operating cash flow to net income has decreased, reflecting potential challenges in cash generation. Despite this, the company demonstrates a capability to sustain free cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.64M	16.97M	17.34M	18.76M	16.21M	17.13M
Gross Profit	5.93M	16.48M	7.00M	18.02M	15.78M	16.50M
EBITDA	3.49M	4.82M	5.17M	7.97M	4.77M	5.97M
Net Income	4.30M	4.56M	4.92M	7.79M	4.55M	5.70M
Balance Sheet
Total Assets	23.60M	26.48M	28.05M	31.20M	27.53M	27.79M
Cash, Cash Equivalents and Short-Term Investments	2.57M	6.53M	7.74M	9.32M	7.62M	3.95M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	5.60M	8.66M	10.23M	13.38M	9.71M	9.96M
Stockholders Equity	18.01M	17.83M	17.83M	17.83M	17.83M	17.83M
Cash Flow
Free Cash Flow	0.00	2.84M	5.77M	4.72M	9.08M	2.79M
Operating Cash Flow	0.00	3.15M	5.85M	4.86M	9.13M	2.89M
Investing Cash Flow	0.00	906.80K	989.98K	58.66K	111.63K	189.04K
Financing Cash Flow	0.00	-4.92M	-7.79M	-4.55M	-5.70M	-1.57M

MeVis Medical Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M3V, the sentiment is Positive. The current price of 25.8 is above the 20-day moving average (MA) of 25.34, above the 50-day MA of 25.08, and above the 200-day MA of 25.02, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 62.42 is Neutral, neither overbought nor oversold. The STOCH value of 64.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:M3V.

MeVis Medical Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	80 Outperform	€45.86M	10.66	24.14%	3.68%	-5.72%	-25.19%
0710	73 Outperform	HK$4.43B	11.07	8.63%	2.92%	19.25%	-10.14%
FME	70 Outperform	€13.16B	20.24	4.95%	3.17%	0.53%	23.79%
DRW3	64 Neutral	€1.09B	12.20	6.82%	3.09%	-0.03%	-14.15%
SRT3	64 Neutral	€13.61B	144.05	5.03%	0.33%	3.80%	33.31%
BIO3	52 Neutral	€1.35B	-45.55	4.97%	0.13%	-18.82%	-113.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%